CoChat

Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children’s Oncology Group (ACNS1221)

Open access
Lafay-Cousin, Lucie, Bouffet, Eric, Strother, Douglas, Rudneva, Vasilisa, Hawkins, Cynthia, Eberhart, Charles, Horbinski, Craig, Heier, Linda, Souweidane, Mark, Williams-Hughes, Chris, Onar-Thomas, Arzu, Billups, Catherine A., Fouladi, Maryam, Northcott, Paul, Robinson, Giles, Gajjar, Amar · 2020 · Journal of Clinical Oncology
Cited by 77

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

PURPOSE: Nodular desmoplastic medulloblastoma (ND) and medulloblastoma with extensive nodularity (MBEN) have been associated with a more favorable outcome in younger children. However, treatment-related neurotoxicity remains a significant concern in this vulnerable group of patients. PATIENTS AND METHODS: ACNS1221 was a prospective single-arm trial of conventional chemotherapy for nonmetastatic ND and MBEN based on a modified HIT SKK 2000 regimen excluding intraventricular methotrexate, aiming to achieve similar outcome (2-year progression-free survival [PFS] ≥ 90%) with reduced treatment-related neurotoxicity. Secondary objectives included feasibility of timely central pathology review and evaluation of tumor molecular profile. RESULTS: Twenty-five eligible patients (15 males and 10 females; median age, 18.7 months) were enrolled. Eighteen patients had ND and 7 had MBEN histology. Three patients had residual disease at baseline. The study closed early because of a higher than expected relapse rate. Twelve patients experienced relapse—local (n= 6), distant (n = 3), and combined (n = 3)—at a median of 9.8 months from diagnosis (range, 8.9-13.7 months), and 2 patients died of disease. Two-year PFS and overall survival rates were 52% (95% CI, 32.4% to 71.6%) and 92% (95% CI, 80.8% to 100.0%) respectively. Patients older than 12 months of age ( P = .036) and ND histology ( P = .005) were associated with worse PFS. No patients with MBEN histology experienced relapse. All tumor samples clustered within the sonic hedgehog (SHH) group. Methylation analysis delineated 2 subgroups, SHH-I and SHH-II, which were associated with 2-year PFS rates of 30.0% (95% CI, 1.6% to 58.4%) and 66.7% (95% CI, 44.0% to 89.4%), respectively ( P = .099). CONCLUSION: The proposed modified regimen of conventional systemic chemotherapy without serial intraventricular methotrexate injection failed to achieve the targeted 2-year PFS of 90%. With this cohort, we prospectively confirmed the existence of two SHH subgroups and observed a trend toward worse outcome for SHH-I patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.00845

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Intertumoral Heterogeneity within Medulloblastoma Subgroups

    Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219

    Self-citation
  • The whole-genome landscape of medulloblastoma subtypes

    Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112 · cited 1×

    “All next-generation sequencing data were harmonized and processed with the same analysis pipelines to ensure consistent germline and somatic mutation calling.(11) All mutations and copy number variation calls were manually curated by inspecting sequence alignments and genome-wide copy number plots.”
    MethodSelf-citation

Show all 2 references

Cited by

See all 77

Metadata

Authors
Lafay-Cousin, L., Bouffet, E., Strother, D., Rudneva, V., Hawkins, C., Eberhart, C., Horbinski, C., Heier, L., Souweidane, M., Williams-Hughes, C., Onar-Thomas, A., Billups, C. A., Fouladi, M., Northcott, P., Robinson, G., & Gajjar, A.
Venue
Journal of Clinical Oncology
Published
2020-01-20
Volume
38
Issue
3
Pages
223-231
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2990858591
Cited by
77
References
2
FWCI
3.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children’s Oncology Group (ACNS1221). https://app.cochat.ai/papers/10.1200/jco.19.00845
The paper
Lafay-Cousin, L., Bouffet, E., Strother, D., Rudneva, V., Hawkins, C., Eberhart, C., Horbinski, C., Heier, L., Souweidane, M., Williams-Hughes, C., Onar-Thomas, A., Billups, C. A., Fouladi, M., Northcott, P., Robinson, G., & Gajjar, A. (2020). Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children’s Oncology Group (ACNS1221). Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.00845

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.